表紙
市場調査レポート

乾性角結膜炎(ドライアイ):パイプライン製品の分析

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 219724
出版日 ページ情報 英文 193 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
乾性角結膜炎(ドライアイ):パイプライン製品の分析 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 193 Pages
概要

ドライアイ症候群は、乾性角結膜炎(KCS)や乾燥角膜炎としても知られている、涙液および目の表面の多因子疾患です。目の表面への潜在的な損傷によって、不快感、視覚障害、涙液層の不安定性をもたらします。目の疲れ、まぶしさ、充血、目やになどの症状が見られます。危険因子は、年齢のほか、レーザー眼科手術、薬剤投薬などが原因となる場合もあります。

当レポートでは、乾性角結膜炎(ドライアイ)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

乾性角結膜炎(ドライアイ)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Alcon, Inc.
  • Allergan, Inc.
  • 生化学工業
  • Merck & Co., Inc.
  • 参天製薬
  • EyeGate Pharmaceuticals, Inc.
  • キッセイ薬品工業
  • Rigel Pharmaceuticals, Inc.
  • Shire Plc
  • Bayer AG
  • InSite Vision Incorporated
  • NovaBay Pharmaceuticals, Inc.
  • Circadian Technologies Limited
  • RegeneRx Biopharmaceuticals, Inc.
  • HanAll Biopharma Co., Ltd.
  • R-Tech Ueno, Ltd.
  • Digna Biotech, S.L.
  • Scynexis, Inc.
  • Lipicard Technologies Limited
  • 千寿製薬
  • Parion Sciences, Inc.
  • Novaliq GmbH
  • Kainos Medicine, Inc.
  • PharmaNova Inc.
  • Resolvyx Pharmaceuticals, Inc
  • SIFI S.p.A
  • Celsus Therapeutics Plc
  • Dompe Farmaceutici S.p.A.
  • Mimetogen Pharmaceuticals Inc.
  • Kala Pharmaceuticals, Inc.
  • Laboratorios Sophia S.A. de C.V.
  • Eleven Biotherapeutics
  • Laurantis Pharma Oy
  • Neuroptis Biotech
  • Dong-A Socio Holdings Co Ltd

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • diquafosol tetrasodium
  • cyclosporine
  • lifitegrast
  • dexamethasone acetate
  • MIMD-3
  • PRO-148
  • EBI-005
  • MB-11316
  • R-348
  • secukinumab
  • cyclosporine
  • RGN-259
  • cyclosporine
  • mapracorat
  • ESBA-105
  • RU-101
  • recoflavone
  • difluprednate
  • ISV-101
  • ozagrel
  • SI-614
  • Recombinant Human Nerve Growth Factor
  • ProtoCure Emulsion Cream
  • Autologous Serum Eyedrops
  • cyclosporine Microemulsion
  • P-17
  • disitertide
  • P-321
  • RX-20001
  • SF-104
  • VGX-100
  • HL-036
  • KeraKlear
  • OPX-1
  • SCY-641
  • NVC-727
  • NVC-638
  • NVC-704
  • NOP-3
  • NOP-5
  • PN-202
  • loteprednol etabonate
  • Lacritin
  • KM-401
  • voclosporin
  • RGN-259
  • Mucin Secretagogues

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7708IDB

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
  • The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
  • The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratoconjunctivitis sicca (Dry Eye) Overview
  • Therapeutics Development
    • Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies
  • Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
    • AB2 Bio Ltd.
    • Akari Therapeutics, Plc
    • Allergan Plc
    • Circadian Technologies Limited
    • Delenex Therapeutics AG
    • Digna Biotech, S.L.
    • Dompe Farmaceutici S.p.A.
    • HanAll Biopharma Co., Ltd.
    • Herantis Pharma Plc
    • Huons Co., Ltd.
    • InSite Vision Incorporated
    • Kala Pharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Kukje Pharmaceutical Industry Co., Ltd.
    • Laboratorios Sophia S.A. de C.V.
    • Lee's Pharmaceutical Holdings Limited
    • Lipicard Technologies Limited
    • Merck & Co., Inc.
    • Mimetogen Pharmaceuticals Inc.
    • Mitotech S.A.
    • Nanomerics Ltd
    • Neuroptis Biotech
    • Novaliq GmbH
    • Ocular Therapeutix, Inc.
    • Oculis ehf
    • OncoNOx ApS
    • Otsuka Holdings Co., Ltd.
    • Parion Sciences, Inc.
    • PharmaReaserch Products Co., Ltd.
    • RegeneRx Biopharmaceuticals, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Samjin Pharmaceutical Co., Ltd.
    • Santen Pharmaceutical Co., Ltd.
    • Seikagaku Corporation
    • Shire Plc
    • Sucampo Pharmaceuticals, Inc.
    • TearSolutions, LLC.
    • Xigen SA
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGN-223575 - Drug Profile
    • AGN-232411 - Drug Profile
    • AVX-012 - Drug Profile
    • Ax-8 - Drug Profile
    • BRM-421 - Drug Profile
    • cinhyaluronate sodium - Drug Profile
    • Cis-Urocanic Acid - Drug Profile
    • Cryosim-3 - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • dexamethasone acetate SR - Drug Profile
    • diclofenac sodium - Drug Profile
    • diquafosol tetrasodium - Drug Profile
    • disitertide - Drug Profile
    • DLX-105 - Drug Profile
    • DMT-220 - Drug Profile
    • HL-036 - Drug Profile
    • HU-007 - Drug Profile
    • ISV-101 - Drug Profile
    • KeraKlear - Drug Profile
    • KJ-14003 - Drug Profile
    • KL-7016 - Drug Profile
    • KPI-190 - Drug Profile
    • Lacripep - Drug Profile
    • lifitegrast - Drug Profile
    • LME-636 - Drug Profile
    • loteprednol etabonate - Drug Profile
    • NOP-3 - Drug Profile
    • NOP-5 - Drug Profile
    • Nov-03 - Drug Profile
    • OC-301 - Drug Profile
    • OPX-1 - Drug Profile
    • OX-1001 - Drug Profile
    • ozagrel - Drug Profile
    • P-321 - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PPL-003 - Drug Profile
    • PRD-005 - Drug Profile
    • PRO-148 - Drug Profile
    • Qi-204 - Drug Profile
    • R-348 - Drug Profile
    • rebamipide - Drug Profile
    • Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
    • RGN-259 - Drug Profile
    • RP-101 - Drug Profile
    • RU-101 - Drug Profile
    • SA-001 - Drug Profile
    • tadekinig alfa - Drug Profile
    • tavilermide hydrochloride - Drug Profile
    • VGX-100 - Drug Profile
    • XG-104 - Drug Profile
    • ZK-003 - Drug Profile
    • zucapsaicin - Drug Profile
  • Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
  • Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Akari Therapeutics, Plc, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Delenex Therapeutics AG, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by PharmaReaserch Products Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H1 2016
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top